Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2OTHER_GOV 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 5Gastrointestinal 3Breast 3Thoracic 2Plasma cell 2Tumor-Agnostic 1Other solid neoplasm 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1

Conditions

Nausea 2Vomiting 1Neoplasms, Plasma Cell 1Multiple Myeloma 1

Interventions

Dexamethasone 479Lenalidomide 297Cyclophosphamide 271Bortezomib 267Melphalan 212Calcium Dobesilate 189fludarabine phosphate 121daratumumab 121Peripheral Blood Stem Cell Transplantation 101fludarabine 99carfilzomib 98Thalidomide 94pomalidomide 92Filgrastim 92Whole-Body Irradiation 88Mycophenolic Acid 88Busulfan 80Tacrolimus 75Granulocyte Colony-Stimulating Factor 72dexamethasone acetate 65ixazomib 62Cyclosporine 59dexamethasone 21-phosphate 56Antilymphocyte Serum 51auricularum 50isatuximab 44Radiotherapy 41Etoposide 40Stem Cell Transplantation 39Methotrexate 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × Olanzapine × Plasma cell × Clear all
NCT06588413 2024-11-22

FONDO-LOW

Augusta University

Phase 3 Recruiting
172 enrolled
Plasma cell

Multiple Myeloma, Nausea

NCT02939287 2024-10-22

Aprepitant- and Olanzapine- Containing Anti-emetic Regimens With High Dose Melphalan

Rush University Medical Center

Phase 3 Completed
52 enrolled 11 charts
Plasma cell

Nausea, Vomiting, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡